Journal article

Effect of omega-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders The NEURAPRO Randomized Clinical Trial

Patrick D McGorry, Barnaby Nelson, Connie Markulev, Hok Pan Yuen, Miriam R Schaefer, Nilufar Mossaheb, Monika Schloegelhofer, Stephan Smesny, Ian B Hickie, Gregor Emanuel Berger, Eric YH Chen, Lieuwe de Haan, Dorien H Nieman, Merete Nordentoft, Anita Riecher-Rossler, Swapna Verma, Andrew Thompson, Alison Ruth Yung, G Paul Amminger



Importance: A promising treatment to prevent onset and improve outcomes in patients at ultrahigh risk for psychosis is dietary supplementation with long-chain ω-3 polyunsaturated fatty acids (PUFAs). Objective: To determine whether treatment with ω-3 PUFAs in combination with a high-quality psychosocial intervention (cognitive behavioral case management [CBCM]) is more effective than placebo plus CBCM. Design, Setting, and Participants: NEURAPRO, a double-blind, placebo-controlled, randomized clinical trial, was conducted from March 1, 2010, to September 30, 2014, in 10 specialized early psychosis treatment services in Australia, Asia, and Europe. The primary analysis used the intention-to-t..

View full abstract


Awarded by Stanley Medical Research Institute

Awarded by NHMRC Australia Program

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by NHMRC

Funding Acknowledgements

This work was supported by grant 07TGF-1102 from the Stanley Medical Research Institute, grant 566529 from the NHMRC Australia Program (Drs McGorry, Hickie, and Yung, and Amminger), and a grant from the Colonial Foundation. Dr McGorry was supported by Senior Principal Research Fellowship 1060996 from the National Health and Medical Research Council of Australia (NHMRC); Drs Yung and Amminger were supported by NHMRC Senior Research Fellowships 1080963 and 566593, respectively; and Dr Nelson was supported by NHMRC Career Development Fellowship 1027532.